21 / 64
REUNIÓN 2
13
8. Sospecha de sobredosis.
9. Evaluación del cumplimiento de los pacientes que presentan eventos
trombóticos durante el tratamiento.
En conclusión, en ciertas situaciones especiales es necesaria la medi-
ción del anticoagulante mediante pruebas básicas de hemostasia. Para
que resultase de utilidad esta medición estas pruebas deberían ser
sencillas, asequibles económicamente y estar disponibles en todos los
laboratorios.
Bibliografía
1.
Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti F, et al.; Italian Federation
of Thrombosis Centers. Questions and answers on the use of dabigatran and perspec-
tives on the use of other new oral anticoagulants in patients with atrial fibrillation. A
consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb
Haemost. 2011;106:868-76.
2. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabi-
gatran etexilate—a novel, reversible, oral direct thrombin inhibitor: Interpretation
of coagulation assays and reversal of anticoagulant activity. Thromb Haemost.
2010;103:1116-27.
3. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of
dabigatran on a large panel of routine or specific coagulation assays. Labora-
tory recommendations for monitoring of dabigatran etexilate. Thromb Haemost.
2012;107:985-97.
4. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct
factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb
Haemost. 2010;104:1263-71.
5. Tripodi A, Chantarangkul V, Guinet C, Samama MM.The International Normalized Ratio
calibrated for rivaroxaban has the potential to normalize prothrombin time results
for rivaroxaban-treated patients. results of an in vitro study. J Thromb Haemost.
2011;9:226-8.
6. Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S. In vitro study of the anti-
coagulant effects of edoxaban and its effect on thrombin generation in comparison to
fondaparinux. Thromb Res. 2012;129:e77-82.